Share Email Print

Proceedings Paper

Intermediate endpoint biomarkers for lung cancer chemoprevention
Author(s): Calum E. MacAulay; Stephen Lam; Helga Klein-Parker; Adi Gazdar; Martial Guillaud; Peter W. Payne; Jean C. Le Riche; Chris Dawe; Pierre Band; Branko Palcic
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Given the demographics of current and ex-smoking populations in North America, lung cancer will be a major problem in the foreseeable future. Early detection and treatment of lung cancer holds great promise for the management of this disease. Unlike cervical cancer, the physical, complete removal/destruction of all dysplastic lesions in the bronchial tree is not possible; however, treatment of the lesions using a chemopreventive agent is. Intermediate biomarkers have been used to screen promising chemopreventive agents for larger population studies. We have examined the natural history of lung cancer development by following a group of subjects at high risk of developing lung cancer using fluorescence endoscopy to identify the areas of abnormality for biopsy. Approximately 900 biopsies have been collected in this fashion and graded by at least two experienced, expert pathologists. Using an interactive version of the Cyto-Savant (Oncometrics Imaging Corp.), cytometric and tissue architectural data were collected from these biopsies. Using only the data from the normal and invasive cancer biopsies, quantitative morphometric and architectural indices were generated and calculated for all the collected biopsies. These indices were compared with Loss of Heterozygosity (LOH) of ten sites commonly associated with cancer. These results and the application of these quantitative measures to two small chemoprevention studies will be reported.

Paper Details

Date Published: 29 April 1998
PDF: 5 pages
Proc. SPIE 3260, Optical Investigations of Cells In Vitro and In Vivo, (29 April 1998); doi: 10.1117/12.307094
Show Author Affiliations
Calum E. MacAulay, British Columbia Cancer Agency (Canada)
Stephen Lam, British Columbia Cancer Agency (Canada)
Helga Klein-Parker, British Columbia Cancer Agency (Canada)
Adi Gazdar, Univ. of Texas Southwestern Medical Ctr. (United States)
Martial Guillaud, British Columbia Cancer Agency (Canada)
Peter W. Payne, British Columbia Cancer Agency (Canada)
Jean C. Le Riche, British Columbia Cancer Agency (Canada)
Chris Dawe, British Columbia Cancer Agency (Canada)
Pierre Band, British Columbia Cancer Agency (Canada)
Branko Palcic, British Columbia Cancer Agency (Canada)

Published in SPIE Proceedings Vol. 3260:
Optical Investigations of Cells In Vitro and In Vivo
Robert C. Leif; Daniel L. Farkas; Robert C. Leif; Bruce J. Tromberg, Editor(s)

© SPIE. Terms of Use
Back to Top